Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HT-PREDICT: Multi-Omics for Antihypertensive Response
NCT05917275Phase 4Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Apr 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of amlodipine, olmesartan, hydrochlorothiazide in primary hypertension, sponsored by Radboud University Medical Center. Started Apr 2024; status: recruiting.
02
Drugs
amlodipineolmesartanhydrochlorothiazide
03
Conditions
primary hypertension
Beyond the preview
Go deeper on NCT05917275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05917275.